{"title":"脂质和聚合纳米载体siRNA递送至大脑","authors":"Sushil Koirala, Kun Cheng","doi":"10.1016/j.jconrel.2025.114286","DOIUrl":null,"url":null,"abstract":"<div><div>Brain diseases refer to any pathological conditions that impair the normal functions of the brain. These mainly include neurodegenerative disorders, brain injuries, and malignant tumors. Researchers have explored various therapeutic approaches to treat these conditions, with gene modulation gaining significant attention in recent years due to its potential to address the root cause of disease. One promising approach is the use of siRNAs as therapeutic agents for brain diseases. Most preclinical studies on siRNA delivery to the brain have employed invasive intracerebral methods to target specific brain regions, posing significant challenges for clinical translation. The challenges associated with the intracerebral route highlight the need for safer, more practical, and patient-compliant alternatives, such as systemic delivery. However, systemic siRNA delivery faces obstacles due to its inherent instability in circulation and the restrictive nature of the blood-brain barrier (BBB). Nanocarriers have emerged as a promising strategy to overcome these challenges. These nanocarriers can be made from various natural, synthetic, or biological materials, with polymers and lipids being the most commonly used due to their biocompatibility, ease of surface modification for targeting, controlled drug release, and improved stability. In this review, we discuss lipid- and polymer-based nanotechnology strategies aimed at overcoming the challenges of siRNA delivery and enhancing its therapeutic potential for treating brain diseases.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"388 ","pages":"Article 114286"},"PeriodicalIF":11.5000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lipid and polymeric nanocarriers for siRNA delivery to the brain\",\"authors\":\"Sushil Koirala, Kun Cheng\",\"doi\":\"10.1016/j.jconrel.2025.114286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Brain diseases refer to any pathological conditions that impair the normal functions of the brain. These mainly include neurodegenerative disorders, brain injuries, and malignant tumors. Researchers have explored various therapeutic approaches to treat these conditions, with gene modulation gaining significant attention in recent years due to its potential to address the root cause of disease. One promising approach is the use of siRNAs as therapeutic agents for brain diseases. Most preclinical studies on siRNA delivery to the brain have employed invasive intracerebral methods to target specific brain regions, posing significant challenges for clinical translation. The challenges associated with the intracerebral route highlight the need for safer, more practical, and patient-compliant alternatives, such as systemic delivery. However, systemic siRNA delivery faces obstacles due to its inherent instability in circulation and the restrictive nature of the blood-brain barrier (BBB). Nanocarriers have emerged as a promising strategy to overcome these challenges. These nanocarriers can be made from various natural, synthetic, or biological materials, with polymers and lipids being the most commonly used due to their biocompatibility, ease of surface modification for targeting, controlled drug release, and improved stability. In this review, we discuss lipid- and polymer-based nanotechnology strategies aimed at overcoming the challenges of siRNA delivery and enhancing its therapeutic potential for treating brain diseases.</div></div>\",\"PeriodicalId\":15450,\"journal\":{\"name\":\"Journal of Controlled Release\",\"volume\":\"388 \",\"pages\":\"Article 114286\"},\"PeriodicalIF\":11.5000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Controlled Release\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168365925008995\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925008995","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Lipid and polymeric nanocarriers for siRNA delivery to the brain
Brain diseases refer to any pathological conditions that impair the normal functions of the brain. These mainly include neurodegenerative disorders, brain injuries, and malignant tumors. Researchers have explored various therapeutic approaches to treat these conditions, with gene modulation gaining significant attention in recent years due to its potential to address the root cause of disease. One promising approach is the use of siRNAs as therapeutic agents for brain diseases. Most preclinical studies on siRNA delivery to the brain have employed invasive intracerebral methods to target specific brain regions, posing significant challenges for clinical translation. The challenges associated with the intracerebral route highlight the need for safer, more practical, and patient-compliant alternatives, such as systemic delivery. However, systemic siRNA delivery faces obstacles due to its inherent instability in circulation and the restrictive nature of the blood-brain barrier (BBB). Nanocarriers have emerged as a promising strategy to overcome these challenges. These nanocarriers can be made from various natural, synthetic, or biological materials, with polymers and lipids being the most commonly used due to their biocompatibility, ease of surface modification for targeting, controlled drug release, and improved stability. In this review, we discuss lipid- and polymer-based nanotechnology strategies aimed at overcoming the challenges of siRNA delivery and enhancing its therapeutic potential for treating brain diseases.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.